Preparation of Microarrays. Amine-functionalized oligosaccharides or proteins were immobilized on commercial N-hydroxysuccinimide (NHS) ester-activated microarray slides (CodeLink Activated Slides; SurModics) using a piezoelectric spotting device (S3; Scienion) such that 64 identical subarrays were contained on each slide. Samples for spotting were diluted in 50 mM sodium phosphate buffer, pH 8.5. Slides were incubated in a humid chamber for 24 h at room temperature to complete coupling reactions. Remaining NHS ester groups were deactivated with 50 mM ethanolamine in 50 mM sodium phosphate buffer, pH 9, for 1 h at 50 °C. Slides were rinsed three times with deionized water, dried by centrifugation (300 x g, 5 min) and stored desiccated until use.
An amount of 2 μg protein (CRM197 or glycoconjugate) was loaded per lane. PageRuler Plus Prestained Protein Ladder 10 to 250 kDa (Thermo Scientific) was used as size marker (3 μL per lane). Samples were run on 10 % SDS-PAGE gels at 20 V cm -1 and stained with 0.5 % (w/v) Coomassie Brilliant Blue R-250 in 50 % (v/v) methanol and 10 % (v/v) acetic acid for 30 min. Stained gels were destained with 50 % (v/v) methanol and 10 % (v/v) acetic acid.
MALDI-TOF MS. Mass spectra were acquired with an Autoflex Speed MALDI-TOF system (Bruker Daltonics). Samples were spotted using the dried droplet technique with 2,5dihydroxyacetophenone (DHAP) as matrix on MTP 384 ground steel target plates (Bruker Daltonics). Samples were prepared by mixing 2 µL of desalted protein sample with 2 µL of DHAP matrix and 2 µL of 2 % (v/v) trifluoroacetic acid (TFA) prior to spotting. The mass spectrometer was operated in linear positive mode. Mass spectra were acquired over an m/z range from 30,000 to 210,000 and data was analyzed with the FlexAnalysis software provided with the instrument.
Pilot Immunization Studies with Glycoconjugate 14. Female, 6-8 weeks old C57BL/6 mice (Charles River) were immunized s.c. with an amount of 14 corresponding to 1 μg of glycan antigen per injection. The immunogen was diluted in sterile PBS to a final volume of 100 μL per injection. For immunizations with Alum adjuvant, 14 was pre-incubated with 1 μL per μg protein of Alum Alhydrogel (Brenntag) the day before, and the mixture was rotated for 24 h at 4 °C. For immunizations with Freund's adjuvant (Sigma-Aldrich), a solution of 14 was combined with an equal volume of Complete Freund's adjuvant (CFA) (priming immunization) or Incomplete Freund's adjuvant (ICFA) (boosting immunizations) to a homogeneous emulsion immediately before injection. For immunizations with AddaVax (similar to MF59) (InvivoGen) a solution of 14 was combined with an equal volume of AddaVax to a homogeneous emulsion immediately before injection (priming and boosting immunizations). The experiments were performed in strict accordance with the German regulations of the Society for Laboratory Animal Science and the European Health Law of the Federation of Laboratory Animal Science Associations and were approved by the Landesamt für Gesundheit und Soziales of Berlin, Germany (protocol number G0135/14). All efforts were made to minimize suffering.
Challenge Studies. 6-8 weeks old female C57BL/6 mice (Charles River, Sulzfeld) were used for immunization experiments. Each injection comprised a volume of 100 µL using sterile PBS as diluent. Sham-immunizations with PBS contained either 17.3 µL Alum or 50 µL AddaVax. One dose of CRM197 contained 17.3 µg protein with either 17.3 µL Alum or 50 µL AddaVax. One dose of 12 contained 7 µg protein, corresponding to 1 µg of 1, and 7 µL Alum. Each dose of 13 contained 16.7 µg protein, corresponding to 1 µg of 2, and 16.7 µL Alum. Each dose of 14 contained 14.3 µg protein, corresponding to 1 µg of 3, and 50 µL AddaVax. Each dose of 15 contained 15 µg protein, corresponding to 1 µg of 4, and 15 µL Alum. Each dose of 16 contained 17.3 µg protein, corresponding to 1 µg of 5, and either 17.3 µL Alum or 50 µL AddaVax. Each dose of formalin-inactivated TcdB contained 75 µg protein and 75 µL Alum. 13 days after the last immunization, mice were rendered susceptible to C. difficile infection with intraperitoneal (i.p.) injections of clindamycin (20 mg per kg body weight) for one day. 33 The next day, mice were challenged via oral gavage with 5x10 7 CFUs of the C. difficile strains M68 or VPI 10463. M68 is a clindamycin-resistant ribotype 017 strain isolated from a hospital outbreak in Dublin, Ireland, expressing toxin B (TcdB) but not toxin A (TcdA). 28,34 VPI 10463 is a highly virulent ribotype 087 strain expressing both toxins. 26, 33 Intestinal colonization was quantified 5 days after the infection by determining the C. difficile CFUs in fecal suspensions that were plated at limited dilutions on selective T.C.C.F.A. agar plates and cultivated for 48 h at 37 °C under anaerobic conditions. The degree of colonization is displayed as CFUs per gram feces. Enterococcus spp. CFUs grown on blood agar plates served as control. Characteristic colonies were counted and identified at random by MALDI-TOF MS analysis. Histopathological analysis of colon samples was performed to determine the degree of colitis.
For passive transfer experiments, mice received 200 µL of pooled sera i.p. on days 0 and 1 with the challenge performed on day 0 two hours after the first serum transfer, using 5x10 7 CFUs of strain VPI 10463. mAbs were applied i.p. on days 0, 1 and 2 (100 µg per injection) and mice were challenged on day 0 two hours after the first antibody transfer, using 5x10 7 CFUs of VPI 10463. Animal experiments were performed in strict accordance with the German regulations of the Society for Laboratory Animal Science and the European Health Law of the Federation of Laboratory Animal Science Associations and were approved by the Regierung von Mittelfranken, Germany (AZ 54-2532.1-47/13).
Microarray-assisted Antibody Binding Analyses. Spotted and quenched microarray slides were blocked using PBS with 1 % (w/v) BSA (PBS-BSA) for 1 h at room temperature, washed three times with PBS and dried by centrifugation. FlexWell 64 grids (Grace Bio-Labs) were applied to yield 64 wells for individual experiments. Slides were incubated with serum samples diluted 1:100 (unless mentioned otherwise) or with processed stool samples diluted 1:100 in PBS with 0.01 % (v/v) Tween-20 and 1 % (w/v) BSA (PBS-T-BSA) for 1 h at room temperature in a humid chamber. Wells were washed three times using PBS with 0.1 % Tween-20 (PBS-T0.1). Grids were removed and slides were dried by centrifugation (300 x g, 5 min). Dried microarrays were incubated with fluorescence-labeled detection antibodies diluted in PBS-T-BSA for 1 h at room temperature in a humid chamber. Following dilutions were used: α-mouse IgA (cat.no. F9384), 1:200; α-mouse IgG (cat.no. A-31574), 1:400; α-mouse IgG1 (cat.no. A-21125), 1:400; anti-mouse IgG2a (cat.no. A-21241), 1:400; α-mouse IgG3 (cat.no. A-21151), 1:200; α-mouse IgM (cat.no. 715-585-140), 1:200. All detection antibodies were from Life Technologies, except α-mouse IgA (Sigma-Aldrich) and α-mouse IgM (Dianova). After incubation with detection antibody, slides were washed three times with PBS-T0.1, rinsed once with H2O and dried by centrifugation. Microarray slides were scanned with a GenePix 4300A scanner (Molecular Devices; Sunnyvale, CA, USA). The photomultiplier tube voltage was adjusted to reveal scans free of saturated signals. Image analysis was carried out with the GenePix Pro 7 software. Background-subtracted mean fluorescence intensity (MFI) values were exported for further analysis.
Processing of Stool Samples for Microarray and ELISA. To fresh stool samples two volumes of PBS supplemented with Protease Inhibitor Cocktail (Sigma-Aldrich) were added. After vigorous vortexing samples were incubated in ice for 1h and then centrifuged (10,000 x g for 20 min). The supernatant was recovered and used for further analyses.
Flow Cytometry. Formalin-inactivated C. difficile bacteria (strain M68 and strain VPI10463) were incubated with murine antisera diluted 1:20 in PBS for 1 h, washed three times with PBS, and stained with anti-mouse IgG FITC produced in goat (cat. no. F0257; BD Biosciences) diluted 1:100 in PBS for 1 h. After three washing steps with PBS, the bacterial cells were subjected to flow cytometry using a FACS Canto II instrument (BD Biosciences). About 2,000 events (strain M68) or 10,000 events (strain VPI 10463) were counted for each individual measurement.
Microbiota Analyses. Fecal specimens were obtained after vaccination, but before infection and analyzed for the composition of the intestinal microbiota by 16S rRNA sequencing. Bacterial genomic DNA from stools was isolated using a ZR Fecal DNA MicroPrep TM kit (Zymo research). The variable V3 and V4 regions of the 16S rRNA genes were amplified with Illumina-Nextera compatible, degenerate region-specific primers: Illumina341F: TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG;
Illumina806R: GTCTCGTGGGCTCG GAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC (Integrated DNA Technologies). Amplicons were gel purified, then dual-indexed barcodes and Illumina flow cell adaptor sequences were attached by eight cycles of PCR, amplicons purified by AMPureXP magnetic beads and quantified using a Qbit device (Invitrogen); normalized, pooled libraries were sequenced on an Illumina MiSeq device using a 600-cycle v3 paired-end kit. Quality-controlled, demultiplexed paired-end reads were joined, classified using the RDP Classifier 2.10 (16S rRNA training set 10) database and results were analyzed using MEGAN5 software 49 and Metagenassist. Numbers of total reads generated per sample are shown in Supplementary Table 1. Quantitative PCR. Bacterial DNA was isolated from mouse feces using the ZR Fecal DNA MicroPrep kit (Zymo Research) according to the manufacturer's recommendations. Previously reported [50] [51] [52] primer and probe sequences for the detection of C. difficile copies were: TcdA-for, CAGTCGGATTGCAAGTAATTGACAA; TcdA-rev, AGTAGTATCTACTACCATTAACAGTCTG; TcdA-probe, FAM-TTGAGATGATAGCAGTGTCAGGATT-TAMRA; TcdB-for, GAAAGTCCAAGTTTACGCTCAAT; TcdB-rev, GCTGCACCTAAACTTACACCA;
TcdB-probe, FAM-ACAGATGCAGCCAAAGTTGTTGAATT-TAMRA; Cdiff16SrRNA1-for, TTGAGCGATTTACTTCGGTAAAGA; Cdiff16SrRNA1-rev, TGTACTGGCTCACCTTTGATATTCA; Cdiff16SrRNA1-probe, FAM-CCACGCGTTACTCACCCGTCCG-TAMRA (C. difficile 16S rRNA gene GenBank accession number: AB548672); Cdiff16SrRNA2-for, GCAAGTTGAGCGATTTACTTCGGT;
Cdiff16SrRNA2-rev, GTACTGGCTCACCTTTGATATTYAAGAG; Cdiff16SrRNA2-probe, TGCCTCTCAAATATATTATCCCGTATTAG (C. difficile 16S rRNA gene GenBank accession number: NR074454). Quantitative PCRs were run on a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific) using the TaqMan Universal Master Mix II (Thermo Fisher Scientific) according to the manufacturer's recommendations and the following cycling conditions: 2 min 50 °C, 10 min 95 °C, (15 sec 95 °C, 1 min 60 °C)x40. Cycle threshold (Ct) values were correlated with C. difficile CFUs to generate standard curves that were used to calculate CFU equivalents.
ELISA. High binding 96-well polystyrene microtiter plates (Corning Inc., Corning, NY, USA) were coated overnight at 4 °C with 10 µg/mL (50 µL/ well) of CRM197 (Pfénex) in PBS. The plates were washed once with PBS-T0.1 and blocked with PBS-BSA for 1h at room temperature. After washing three times with PBS-T0.1, the plates were incubated with serum or processed stool samples diluted 1:100 in PBS-BSA (50 µL per well) for 1h at 37 °C. The plates were washed three times with PBS-T0.1 and incubated for 1h at room temperature with HRP-conjugated goat anti-mouse IgG (Sigma-Aldrich) diluted 1:10,000 in PBS-BSA (50 µL per well). Plates were washed three times with PBS-T0.1 and developed using 3,3',5,5'-tetramethylbenzidine (BD Biosciences). The reaction was stopped by adding 2% H2SO4 and absorbance at 450 nm was recorded.
Histopathology. Intestinal tissue obtained from the ascending, transverse and descending colon was fixed in 10% buffered formalin, embedded in paraffin, and cut into 2 µm thick sections. Colonic sections were deparaffinized, stained with H&E by the Department of Pathology of the FAU Erlangen-Nürnberg, and evaluated microscopically in a double-blinded manner. Briefly, the intestinal damage shown in the presented figures was evaluated in at least 5 colonic tissue sections per mouse using the following parameters: (a) inflammatory infiltrate, (b) submucosal edema, (c) epithelial damage and the number of intraepithelial lymphocytes (IELs) (d), lymph follicles (LF) (e) and crypt abscesses (CA) (f). A histologic grading of the severity of the tissue damage was performed for each parameter a-c (score between 0 and 3) and the number of IELs (score of 0: 0 IELs, score of 1: < 5 IELs, score of 2: < 10 IELs and score of 3: > 10 IELs) or lymph follicles (LF) and crypt abscesses (CA) (score of 0: 0 LF or CA, score of 1: 1 LF or CA, score of 2: 2 LF or CA and score of 3: 3 LF or CA), leading to a cumulative score between 0 (no signs of inflammation) and 18 (very severe inflammation and epithelial damage). For the initial challenge studies with strain M68, inflammation scores reflect the average of the three tissue sections with most prominent pathology obtained from at least five colon sections per mouse. For the repeat challenge studies, inflammation scores reflect the average of the three tissue sections with most prominent pathology obtained from at least 15 (M68) or 10 (VPI 10463) colon sections per mouse. . Subpanel 8 shows small localized infiltrates after infection in a mouse immunized with 15, subpanel 9 lymph follicles with hyperplasia after infection in a mouse immunized with 14. Subpanel 10 shows the detection of intraepithelial lymphocytes of a sham-immunized mouse. Tissue sections without pathological signs from
